MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.
On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.
MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.
The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.
MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.
—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—
MIAMI – February 27, 2018 – The Parkinson’s Foundation today announced the election of Jena E. Abernathy to its board of directors.
NEW YORK & MIAMI, FEBRUARY 16, 2018 — The Parkinson’s Foundation is proud to announce that Moving Day, A Walk for Parkinson’s, has funded more than $17 million in mission services to make life better for people living with Parkinson’s disease (PD).
NEW YORK & MIAMI - January 10, 2018 - The Parkinson’s Foundation today announced the enrollment of the 10,000th Parkinson’s patient and the discovery of critical new learnings in what represents the largest clinical study of Parkinson’s disease in history.